







National Vascular Registry - Outlier Policy for units/trusts/health boards

Introduction

This document sets out the process by which unit level performance will be assessed within the National Vascular Registry (NVR). It is designed to provide transparency about data handling and analysis, and a robust process for managing hospitals with indicator values that fall outside the expected range of performance (i.e. are flagged as an "outlier"). This version of the outlier policy will be applied to the analyses by the NVR team carried out from 2024.

Background

The NHS mandate and "Good Medical Practice" require clinicians to provide accurate, up-to-date information about their clinical practice to ensure patient safety. Revalidation and the issuing of a licence to practice are predicated on demonstrating acceptable clinical performance.

The Medical Director of the NHS has made it clear that the responsibility for maintaining and providing accurate data rests with individual clinicians both in terms of coding of their work and the submission of clinical activity data to national audits where indicated.

In order to support clinicians in this requirement, the Department of Health has made available public funds to support national clinical audit. The Vascular Society has obtained financial support to set up and run the National Vascular Registry (NVR) in partnership with the Clinical Effectiveness Unit (CEU) at the Royal College of Surgeons of England. The NVR is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit and Patient Outcomes Programme. HQIP acts as the data controller for the NVR and has responsibility for managing how NVR data are used. The NVR team act as data processors on behalf of HQIP and manage the data collection, analysis and publication of results.

Responsibility for data entry rests with local clinical vascular teams, supported by their NHS trust / health boards. NHS trusts / health boards have a duty to provide both clinical audit data under national quality accounts, and to ensure high quality data are submitted. The collection of data on the eligible procedures (abdominal aortic aneurysm (AAA) repair, carotid intervention, and lower-limb interventions for peripheral arterial disease (PAD)) is performed through a bespoke online data collection tool. To support data collection, the NVR team will provide hospitals with information on case ascertainment and coding quality.

The NVR team perform regular assessments of hospital performance and make the results publicly available. The measures are selected from a variety of sources, such as the academic literature, NICE, and national commissioning targets, and cover clinical processes and patient outcomes. Reporting schedules will be regularly communicated to clinical vascular teams to allow them sufficient time to review their data and ensure it is up to date prior to analysis and reporting.









Principles for managing providers identified as "outliers" on a performance indicator

The guiding principles adopted by the NVR are outlined below. Information about choice of indicators will be publicly available and included in reports.

1. Performance indicators

Performance indicators are intended to provide a valid measure of a provider's quality of care. Postoperative death is the outcome measure for AAA repair, lower limb angioplasty, lower limb bypass and lower limb amputation. For carotid procedures the outcome measure is stroke and/or death within 30 days. Any additional outcomes will be selected based on their relevance to the procedure.

Where appropriate, we will report process measures, such as the time from symptom to intervention for carotid surgery. It is intended that such indicators will provide information on service quality for the profession and the public.

These performance indicators are usually based on the most recent three years of data submitted to the NVR, but trusts / health boards will be notified in advance if a specific indicator is based on a different time period. From 2024, the NVR will be reporting on outliers based on non-participation to the NVR, either in full or by not submitting any data for a given procedure, where the NHS trust/health board provides that procedure.

The timeframe for the current performance indicators can be found on our website.

2. Expected performance

The expected performance on an indicator may be defined in two ways. In some circumstances, it will be based on external sources such as research evidence and agreed standards of care (as outlined in VS Quality Improvement Frameworks). More generally, the expected level of performance will be derived from the NVR. This level will be calculated using statistical methods, and be presented using appropriate types of graphs, such as funnel plots.

3. Data quality

We will report three aspects of data quality, namely:

- case ascertainment: This is the number of patients entered into the NVR compared to the number eligible, derived from external data sources. This will help to inform clinicians, commissioners and the public about the generalisability of the reported outcomes.
- data completeness: this refers to the completeness of the data submitted by hospitals for each patient. Complete data is required for accurate analysis and reporting. Without complete data, indicator values for units may be unrepresentative of actual practice.
- data accuracy: this will be tested using consistency and range checks, as well as external validation against HES. It may involve other methods of validation such as peer review.

The NVR has extensive data validation rules to reduce the risk of missing values, and it is rare for the NVR not to be able to analyse the outcomes of a particular organisation because of poor quality data. If the data supplied by an organisation is so incomplete that the results of any analysis would be unreliable, it is automatically treated as a potential outlier.









4. Case-mix (risk) adjustment

The comparison of outcomes across health care providers must take account of patient characteristics so that differences in outcomes between providers are not due to the differences in the types of patient they treat. This typically involves taking into account a patient's age, sex, disease severity and the existence of any other co-morbidity.

We will report on details of the risk-adjustment model and its performance characteristics. The NVR team will use the national data to develop appropriate risk-adjustment methods for each procedure.

5. Detection of a potential outlier

Statistically derived limits around the expected level of performance (e.g. mean mortality following AAA repair) will be used to define whether or not a provider is a potential outlier. A statistical model will be used to define these limits using established methods.

A provider will be flagged as a potential outlier if the value on an outcome indicator is more than a specified number of standard deviations (SD) from the expected performance level. The threshold for being flagged an outlier has been set at 3 SD from the expected level and is defined as an 'alarm.' Those providers who fall between 2 SD and 3 SD from the expected level of performance will be considered as an 'alert'. These thresholds are consistent with common practice¹.

It is important to note that these are definitions of statistically significant differences from expected performance. Such differences may not be clinically important if the indicator value is based on large numbers of patients. Where possible, the statistical methods used to generate the control limits will be refined so that they reflect clinically important differences.

6. Management of a potential outlier

The management of a potential outlier involves various people:

- The NVR team: the team responsible for managing and running the audit nationally. This
 comprises the Director of the CEU at the Royal College of Surgeons and the Chair of the
 Audit and QI committee of the Vascular Society in his/her role as the clinical lead for the
 audit.
- The provider is flagged as a potential outlier. If it is the provider that is flagged, the process will involve the lead clinician of the vascular unit (i.e., the clinical lead for the team delivering care within the vascular unit under scrutiny).

In addition, the provider clinical governance lead (responsible for clinical governance in the provider NHS trust), the provider Medical Director, and Chief Executive may need to be involved.

The following table indicates the seven stages that will be followed in managing a potential outlier, the actions that need to be taken, the people involved and the maximum time scales. It aims to be feasible and fair to providers identified as potential outliers and sufficiently rapid so as not to unduly delay the publication of comparative information. If after a review of their data, their level of performance is still beyond the 3 SD control limit, the provider will be flagged as an outlier.

¹ Spiegelhalter DJ. Funnel plots for comparing institutional performance. Stat Med 2005; 24: 1185-202.









7. Cause for concern

In the rare circumstances in which information submitted to the NVR could reasonably suggest the presence of very serious issues with clinical practice or system failure that presents a risk of harm to patients, the NVR will implement the escalation process described in Table 3 in the following guidance published February 2019: https://www.hqip.org.uk/wp-

content/uploads/2019/02/NCAPOP-Cause-for-Concern-Guidance-Final-E-and-W-Feb-2019.pdf

Stage	What action?	Who?	Within how many working days?
1	Providers with a performance indicator value beyond the alarm threshold require careful scrutiny of the data handling and analyses performed to determine whether there is: 'Alarm status not confirmed' • potential outlier status not confirmed • data and results revised in NVR records • details formally recorded. 'Alarm status confirmed' • potential outlier status persists • proceed to stage 2	NVR Team	10
2	The Lead Clinician in the provider organisation is informed about the potential outlier status and requested to identify any data errors or justifiable explanation/s. All relevant data and analyses by the NVR will be made available to the Lead Clinician.	NVR Director and Clinical Lead	5
3	Lead Clinician to provide written response to NVR governance team.	Provider Lead Clinician	25









Stage	What action?	Who?	Within how many working days?
4	Review of Lead Clinician's response to determine: 'Alarm status not confirmed' • It is confirmed that the data originally supplied by the provider contained inaccuracies. Re-analysis of accurate data indicates that the level of performance is now within the alarm control limits, and the provider is not flagged as an outlier. • Data and results will be revised in NVR records. Details of the provider's response and the review result recorded. • Lead Clinician notified in writing.	NVR Team	20
	 'Alarm status confirmed' It is confirmed that, although the data originally supplied by the provider were inaccurate, analysis still indicates that the level of performance is still beyond the alarm control limits, and the provider is an outlier; or It is confirmed that the originally supplied data were accurate, thus confirming that the provider is an outlier. proceed to stage 5 		
5	Contact Lead Clinician by telephone, prior to written confirmation of outlier status; copied to Provider clinical governance lead / Medical Director and Chief Executive. All relevant data and statistical analyses, including previous response from the lead clinician, will be made available to the Provider clinical governance lead / Medical Director and Chief Executive. Non-participant trusts/health boards will be included from this step.	NVR Director and Clinical Lead NVR Team	5
	For providers in England, the CQC, NHS England and HQIP will be notified at this stage. For providers in Wales, the Welsh Government and HQIP will be notified at this stage.		









Stage	What action?	Who?	Within how many working days?
6	Results for providers in England can be published at this time in comparative information that identifies providers (e.g., in annual report of NVR).	NVR Team	
	For providers in Wales, acknowledgement of receipt of the letter confirming that a local investigation will be undertaken with independent assurance of the validity of this exercise.	Provider Chief Executive	10
7	The CQC advise that during their routine local engagement with the providers, their inspectors will: • Encourage Trusts to identify any learning from their performance and provide the CQC with assurance that the Trust has used the learning to drive quality improvement • Ask the Trust how they are monitoring or plan to monitor their performance.	England – CQC	
	The Welsh Government monitors the actions of organisations responding to outliers and takes further action as and when required. The Healthcare Inspectorate Wales (HIW) does not act as regulator and cannot take regulatory action in relation to NHS providers. However, HIW can request information on the actions undertaken by organisations to ensure safe services are being delivered. The Welsh Government can share information with HIW where appropriate and advise on the robustness of plans in place to improve audit results and outcomes.	Wales – Healthcare Inspectorate Wales	
8	For England: if an investigation has been conducted in the Trust into an alarm outlier status, it is required that the CQC and audit provider would be provided with the outcome and actions proposed. This will be published by the NVR alongside the annual report. Further if there were no response, the NVR would publish this absence of a response.	NHS Trust Medical Director NVR Team	









8. Management of alert and outlier triggers.

An "alert" indicates that the vascular unit has an indicator value (e.g., postoperative mortality rate) that is between 2 and 3 SDs from the expected level of performance.

Stage	What action?	Who?
1	Units with a performance indicator value beyond the alert threshold require careful scrutiny of the data handling and analyses performed to determine whether there is an issue with the data. Units flagged as "alerts" will not be subject to the full review process as outlined in section 6. This is because 1 in 20 consultants units be expected to have	NVR Team
	this size of difference from the national average simply from random variation alone.	
2	The Lead Clinician in the provider organisation is informed about the alert status. All relevant data and analyses by the NVR will be made available to the Lead Clinician if required. It is not expected that there will be a full re-analysis of the unit's data if any corrections are made to it.	NVR Team and provider Clinical Lead
3	For English NHS trusts, the NVR team will also notify HQIP, NHS England and the CQC. For Welsh Health Boards, the NVR team will also notify HQIP and the Welsh Government.	NVR Team
4	The expectation is that units should use 'alert' information as part of their internal quality monitoring process. They should review alerts in a proactive and timely manner, acting accordingly to mitigate the risk of care quality deteriorating to the point of becoming an alarm level outlier.	Provider Clinical Lead

The role of the NVR

The primary role of the NVR is to support clinical teams in providing high-quality, robust clinical audit data. It is anticipated that "alarms" will be triggered rarely and that a regular reporting cycle will help to drive up clinical quality. Where such triggers are activated, the NVR team will seek to provide additional help to providers wanting to review data entry and quality.

Units should be aware that while the NVR has a duty to report on the data it holds, the NVR is not responsible for the accuracy and completeness of the data submitted. This responsibility rests with the clinical teams/units/NHS trust providing the service to patients. Issues with clinical audit data (either case ascertainment or data quality) must be addressed by the unit/trust concerned.

Units or clinicians with concerns about data quality are urged to contact the NVR team at the Royal College of Surgeons of England at the earliest opportunity to discuss them.

Clinical Effectiveness Unit, December 2024, version 2.2